Morgan Stanley Invest Advisors has filed plans with the SEC for a biotechnology fund. The proposed Morgan Stanley Biotechnology Fund will sport A, B, C and D class shares and be managed by the manager's Sector Funds Equity team, including Peter Dannenbaum and Alexander Denner.
* * *
Global Crossing Investors Try for Second Life
Global Crossing investors, including those who purchased shares through the 401(k) plan, may not be wiped out if a group of shareholders get their way. The group led by Hartford-based Coburn Meredith has filed an alternative work out plan with the U.S. Bankruptcy Court in Manhattan that would give the boot to current Global Crossing executives and nix the sale of the company. The plan calls for raising about $1 billion in new capital through the issuance of warrants.
Stay ahead of the news ... Sign up for our email alerts now